Nature Reviews Drug Discovery contents November 2013 Volume 12 Number 11 pp 809-885

Advertisement
In vitro drug combination simplified In vitro drug-drug interaction experiments are a vital step in the discovery of new drugs and treatments, but they can also be expensive, time consuming and frustrating to run. That's all about to change. The HP D300 makes designing and running combination studies simpler, faster and less expensive than ever before. Talk to Tecan www.tecan.com Join our webinar 'Drug-drug combinations made simple' on Nov 6th
TABLE OF CONTENTS
November 2013 Volume 12 Number 11		Advertisement
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Metabolic targets for cancer therapy Lorenzo Galluzzi, Oliver Kepp, Matthew G. Vander Heiden & Guido Kroemer	Frontiers in Pharmacology publishes articles on the most outstanding discoveries across a wide research spectrum of Pharmacology including basic pharmacology, clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Our open access platform and research network allows you to discuss and disseminate your research. We accept a variety of article types including mini reviews and opinion articles.  Submit your paper today
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Emerging therapeutic targets for T2DM  Type 2 diabetes mellitus (T2DM) is one of the most prevalent noncommunicable diseases in the world. New therapeutic targets for T2DM have been uncovered in the past decade, some of which have reached clinical application. This Nature Reviews Endocrinology collection gives an overview of the emerging therapeutic targets for T2DM, discussing promising avenues uncovered from basic, translational and clinical research. The collection is free for 6 months thanks to support from Boehringer Ingelheim
In this issue p809 | doi:10.1038/nrd4162 Full Text
Comment: Bringing together the academic drug discovery community Barbara S. Slusher, P. Jeffrey Conn, Stephen Frye, Marcie Glicksman & Michelle Arkin p811 | doi:10.1038/nrd4155 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Make or break for first splice-modulating agents Asher Mullard p813 | doi:10.1038/nrd4151 If Duchenne muscular dystrophy drugs that modulate gene splicing can overcome key hurdles, they could boost enthusiasm for related antisense oligonucleotides in other indications. PDF
IL-17 antibodies gain momentum Man Tsuey Tse p815 | doi:10.1038/nrd4152 A Phase III trial for a first-in-class psoriasis drug provides encouraging data, but the emerging agents still have to prove their worth in a crowded autoimmune market. PDF
NEWS IN BRIEF Approving pre-surgery cancer drugs p817 | doi:10.1038/nrd4172 PDF
Malaria vaccine on track p817 | doi:10.1038/nrd4173 PDF
First-in-class PI3K inhibitor advances p817 | doi:10.1038/nrd4174 PDF
BIOBUSINESS BRIEFS Trial watch: Success in amyloidosis trials supports potential of systemic RNAi Sarah Crunkhorn p818 | doi:10.1038/nrd4165 PDF
BIOBUSINESS BRIEFS Deal watch: Biogen and Amicus to pursue genetically validated Parkinson's disease target Monica Hoyos Flight p819 | doi:10.1038/nrd4166 PDF
PATENT WATCH A promise to a court doesn't avoid infringement Charlotte Harrison p820 | doi:10.1038/nrd4170 PDF
Patents related to glycine transporters Charlotte Harrison p821 | doi:10.1038/nrd4171 PDF
AN AUDIENCE WITH Dan Tagle p822 | doi:10.1038/nrd4153 The NIH's Dan Tagle discusses the promise of exRNA, the focus of a US$17 million funding programme. PDF
FROM THE ANALYST'S COUCH Advances in prostate cancer treatment Dominic Trewartha & Kimberley Carter p823 | doi:10.1038/nrd4068 Several new drugs for advanced prostate cancer were approved in the past few years, and the pipelines are bristling with compounds that have diverse mechanisms of action. This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer. PDF
RESEARCH HIGHLIGHTS Top Metabolic disorders: FGF21 analogue shows promise in the clinic p825 | doi:10.1038/nrd4157 PDF Antibacterials: Resistance-guided discovery of new antibiotics p826 | doi:10.1038/nrd4158 PDF Anticancer drugs: IDH2 drives cancer in vivo p826 | doi:10.1038/nrd4160 PDF Neurodegenerative disorders: A PIR-fect storm p827 | doi:10.1038/nrd4159 PDF Lysosomal storage diseases: Thioesterase mimetic reduces toxicity p828 | doi:10.1038/nrd4156 PDF IN BRIEF Biochemical engineering: Ta da! A way to add fluorine to natural products | Infectious disease: Combating visceral leishmaniasis | G protein-coupled receptors: Crystal structures aid ligand mechanistics PDF Drug Discovery JOBS of the week Tenure-Track Faculty Position in Cancer Biology Stony Brook University PhD Program In Biomedical Engineering Khalifa University Faculty Position, University of California, San Francisco: Chemical Technologies for Biological Discovery University of California - San Francisco Junior Research Group Leader (M / F) German Cancer Research Center (DKFZ) More Science jobs from Drug Discovery EVENT 6th International Conference on Drug Discovery and Therapy 12.02.14 Dubai More science events from
Advertisement
Discover Research Partnerships with Boehringer Ingelheim Our research teams know that they can only tackle some of the most important challenges in medicine today if we work together with colleagues outside our organisation. We invite academic institutions, non-profit research centres and external industry partners to help us deliver a better future for patients. Visit http://discoveringtogether.boehringer-ingelheim.com
REVIEWS		Top
Metabolic targets for cancer therapy Lorenzo Galluzzi, Oliver Kepp, Matthew G. Vander Heiden & Guido Kroemer p829 | doi:10.1038/nrd4145 Cellular metabolism is substantially altered during oncogenesis and tumour progression, and targeting these metabolic changes is being actively pursued in the development of selective antineoplastic agents. Here, Kroemer and colleagues discuss the intimate relationship between metabolism and malignancy, focusing on therapeutic strategies and emerging agents targeting the metabolic rearrangements of cancer cells. Abstract | Full Text | PDF | Supplementary information
MicroRNAs and other non-coding RNAs as targets for anticancer drug development Hui Ling, Muller Fabbri & George A. Calin p847 | doi:10.1038/nrd4140 Non-coding RNAs (ncRNAs) are involved in the development of a number of diseases, including cancer, and the first ncRNA-targeted therapeutics have recently entered clinical trials. Here, Calin, Ling and Fabbri present the latest insights into ncRNA biology, with a focus on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), and discuss how these inform therapeutic strategies that modulate ncRNAs in cancer. Abstract | Full Text | PDF
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain Robert J. Harvey & Benjamin K. Yee p866 | doi:10.1038/nrd3893 Glycine transporters are important regulators of the level of glycine, which can act as both an inhibitory neurotransmitter and a modulator of neuronal excitation. Here, the authors discuss the potential of glycine transporters as novel therapeutic targets for schizophrenia, alcohol dependence and pain. Abstract | Full Text | PDF
Advertisement
Web Collection on Hepatocellular carcinoma from Nature Reviews Clinical Oncology and Nature Reviews Gastroenterology & Hepatology This web collection includes a selection of articles covering key aspects of the pathogenesis and treatment of HCC, including insights into disease pathways and possible future therapeutic targets.  FREE for a limited time!  This Collection is produced with educational support from Onyx Pharmaceuticals, Inc. and Bayer Healthcare LLC
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.